Skip to main content

Table 3 Quantitative analysis of the mass enhancement contrast

From: Multimodel magnetic resonance imaging of mass-forming autoimmune pancreatitis: differential diagnosis with pancreatic ductal adenocarcinoma

 

AIP (N = 17)

PDAC (N = 30)

P value

ACROC*

P value#

ContrastUP, mean (range, SD)

0.79 (0.55–1.06, 0.16)

0.66 (0.44–0.98, 0.11)

0.003

0.735 (0.579–0.892)

0.172

ContrastAP, mean (range, SD)

0.85 (0.45–1.18, 0.21)

0.55 (0.22–1.16, 0.19)

 < 0.001

0.851 (0.734–0.968)

0.885

ContrastPP, mean (range, SD)

1.10 (0.73–1.63, 0.26)

0.70 (0.21–1.38, 0.28)

 < 0.001

0.851 (0.745–0.957)

0.733

ContrastVP, mean (range, SD)

1.28 (0.83–1.92, 0.34)

0.79 (0.24–1.48, 0.30)

 < 0.001

0.859 (0.755–0.963)

 

ContrastDP, mean (range, SD)

1.30 (0.83–1.79, 0.28)

1.00 (0.30–1.53, 0.33)

0.003

0.749 (0.607–0.891)

0.009

  1. UP unenhanced phase, AP arterial phase, PP pancreatic phase, VP portal venous phase, DP delayed phase
  2. *AUROC for differentiating between AIP and PDAC (95% CI)
  3. #Compared to AUROC of ContrastVP